Group 1: Company Overview and Market Position - Tianma Microelectronics has established itself as a leading player in the automotive display sector, with over 30 years of experience and a comprehensive professional team covering R&D, manufacturing, quality, marketing, and supply chain management [2] - The company has maintained the highest global shipment volume for automotive TFT-LCD and automotive instrument displays since 2020, and is expected to achieve the same for automotive Head-Up Displays (HUD) in 2024 [2][3] - In the first three quarters of 2025, the overall sales of the automotive business increased by approximately 24% year-on-year, driven by growth in traditional automotive displays, automotive electronics, and domestic new energy sectors [2] Group 2: Profitability and Market Challenges - The gross margin of the automotive business has remained stable year-on-year in the first three quarters of 2025, despite facing competitive pressures and price challenges in the market [4] - The company aims to enhance product complexity and integration in automotive displays, focusing on high-value products to maintain a robust gross margin [4] Group 3: OLED and Micro-LED Developments - Since 2025, the demand for flexible OLED mobile display products has seen moderate growth, while market prices have faced pressure due to competitive dynamics [5] - The company has been actively developing its Micro-LED technology since 2017, focusing on automotive and splicing display applications, and has launched several industry-leading Micro-LED products [6][7] Group 4: Supply Chain and Material Localization - Tianma has established partnerships with thousands of suppliers to enhance material diversification and localization, resulting in a continuous increase in the localization rate of materials [8] - The company is committed to supporting domestic suppliers and strengthening supply chain resilience [8] Group 5: Innovation and New Technologies - The MPG platform has been established to explore non-display applications based on panel technology, with ongoing collaborations in areas such as smart antennas and flexible sensors [9] - The company is in the incubation phase for several technologies, with some already in small-scale production [9] Group 6: Market Value Management - The company emphasizes market value management, integrating it into its assessment system, and has implemented various measures to enhance shareholder value and investor confidence [10] - Initiatives include the release of valuation enhancement plans and commitments from major shareholders not to reduce their stakes [10]

Group 1: HUD Product Development - The company's HUD products have established partnerships with numerous domestic and international automotive clients, expanding their model coverage continuously. Notable new clients include Geely, Xpeng, Great Wall, Chery, FAW, Changan, BYD, Volkswagen, STELLANTIS, Hyundai, and Seres, with multiple designated projects based on the Lcos imaging solution [2] - As of the end of 2025, the global cumulative shipment of HUD products has exceeded 4 million units, maintaining a leading position in the industry. The company expects continued high growth in HUD products as more new projects enter the mass production phase [2] Group 2: AI Box Product Introduction - The AI Box product has been launched to address the increasing demand for personalized and intelligent features in the automotive sector, successfully securing designated projects with well-known domestic automotive platforms [3] - The AI Box enables data processing on the edge, ensuring user data security and privacy while integrating various sensors to create a comprehensive perception system for improved user interaction and driving safety [3] Group 3: Expansion in Two-Wheeler Market - The two-wheeler market is transitioning towards intelligence and high-end features, presenting significant market potential. The company has leveraged over 20 years of experience in the automotive electronics industry to penetrate this market effectively [3] - Recent projects for liquid crystal displays and domain controllers have been secured with multiple two-wheeler manufacturers [3] Group 4: Magnesium and Zinc Alloy Business Development - Magnesium alloy products are widely used in automotive lightweight applications, with significant growth in new project orders expected in 2025 [3] - Zinc alloy precision die-casting products are gaining traction due to their excellent thin-wall forming and corrosion resistance, serving clients like TE Connectivity, Molex, Amphenol, and Aptiv [3] - The market for precision die-casting in aluminum, magnesium, and zinc alloys is expanding, with ongoing efforts to increase production capacity based on current orders [4]

Group 1: Strategic Planning and Business Model - Northeast Pharmaceutical aims to implement a "main business focus, comprehensive industrial expansion" strategy to enhance profitability and establish a sustainable profit model, maintaining stable growth in line with industry standards [2][3] - The company emphasizes "innovation-driven, digital empowerment, green transformation, and open cooperation" as core strategic directions to build competitive advantages across the entire industry chain [2] Group 2: Impact of Shareholder Changes - After becoming a controlling shareholder in 2018, Fangda Group introduced advanced market-oriented management models, significantly improving Northeast Pharmaceutical's operational efficiency and profitability [4] - The company has shown continuous profit growth over the past five years, indicating resilience and sustainable development capabilities [4] Group 3: Revenue Structure and Future Trends - As of the first three quarters of 2023, the company's revenue structure is stable, with approximately 60% from pharmaceutical manufacturing and 40% from pharmaceutical commerce [6] - Traditional businesses face challenges from industry policies and market competition, while innovative drug segments are expected to drive future growth [6][7] Group 4: Innovation and R&D Developments - The acquisition of a 70% stake in Beijing Dingcheng Peptide Source Biotech Co., Ltd. in 2024 allows Northeast Pharmaceutical to enter the TCR-T and CAR-T cell therapy fields, with promising products already in clinical trials [4][6] - Dingcheng Peptide has established a comprehensive R&D system, focusing on cell and gene therapy, and has received multiple recognitions as a high-tech enterprise [9][10] Group 5: Challenges and Market Dynamics - The company faces challenges in balancing high R&D costs with short-term cash flow pressures, particularly in the competitive cell therapy market [7] - The transition from traditional chemical pharmaceuticals to a dual-driven model of traditional and innovative biopharmaceuticals is critical for future growth [7] Group 6: Talent Acquisition and Team Structure - Dingcheng Peptide's R&D team includes 18 PhDs and 59 master's degree holders, ensuring expertise across key areas of drug development [10] - A recruitment plan aims to onboard 300 master's and doctoral graduates by 2025 to strengthen the R&D capabilities in cell therapy [10]

Group 1: Impact of Nickel Price - The recent rise in nickel prices has not significantly impacted the company's performance due to effective procurement strategies and pricing adjustments [1] - The company uses a cost-plus pricing model based on the spot market prices of electrolytic nickel and other metals, with adjustments for market conditions and customer factors [1] Group 2: Product Types and Applications - The company produces small and medium-sized components, including special structural parts, standard fasteners, high-strength fasteners, seals, and actuators, primarily for the aerospace sector [1] - There is potential for expansion into high-end equipment manufacturing in fields such as gas turbines, high-speed rail, marine, and petrochemicals [2] Group 3: Future Development Strategy - The company aims to consolidate its existing main business products while focusing on the development of high-end civilian products [2] - Future goals include establishing a product structure based on military and high-end civilian product support to ensure sustainable high-quality development and increased investor returns [2] - The company is committed to advancing in the high-temperature alloy and advanced metal materials industry, targeting high-performance alloy materials and products for aerospace, naval, and energy sectors [2]

证券代码：300480 证券简称：光力科技 债券代码：123197 债券简称：光力转债 光力科技股份有限公司投资者关系活动记录表 编号：20260123 | | □特定对象调研 □分析师会议 | | --- | --- | | □媒体采访 投资者关系活动 | □业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 □现场参观 | | | √其他 | （投资者电话交流会） | | 参与单位名称及 | 中金资管：陈俊、崔海亮；浙商证券：厉秋迪、褚旭、胡嘉、赵洪。 | | 人员姓名 | | | 时间 2026 年 | 1 月 23 日 15:00-16:00 | | 地点 线上交流 | | | 上市公司接待人 | 总经理、董事：胡延艳 | | 员姓名 | 证券事务代表：关平丽 | | | 公司管理层简要介绍公司情况，并与投资者就公司半导体封测装备 | | | 业务、物联网安全生产监控装备业务的经营情况及其他投资者关心的问 | | | 题进行沟通交流，主要交流内容如下： | | | 1、截至目前，公司订单和发货情况？ | | | 答：感谢您的关注！公司国产化机械划切设备以其媲美国际一流产 | | | 品的性 ...

Group 1: Investor Relations Activities - The company conducted an investor relations activity on January 23, 2026, with 53 institutional investors participating [1] - Activities included a company tour, production workshop visit, and a presentation on the company's development [1][2] Group 2: Company Performance and Strategy - The company aims to embrace AI and enhance its technological leadership in the global PCB manufacturing sector [1][3] - High-end products have significantly increased in proportion, driving rapid growth in company performance [3] Group 3: Production Capacity and Expansion - The company maintains a good order backlog and production capacity utilization, with ongoing expansion efforts [3][4] - Domestic production facilities in Huizhou are gradually being put into operation, while overseas facilities in Thailand and Vietnam are progressing as planned [3][4] Group 4: Product Development and Market Position - The company has achieved mass production capabilities for high-precision circuit boards and is advancing in the development of next-generation AI server products [3][4] - The company is actively involved in the research and development of new technologies and materials, collaborating closely with major clients [4] Group 5: Raw Material Supply and Pricing - The company has established stable relationships with key raw material suppliers, ensuring a steady supply [4] - Strategies are in place to mitigate the impact of raw material price fluctuations on product pricing [4] Group 6: Hong Kong Listing Progress - The company is in the process of issuing H shares and has submitted the application to the Hong Kong Stock Exchange [5] - The listing is subject to approval from regulatory authorities and market conditions, with ongoing updates to be provided [5]

Group 1: Company Overview and Strategic Direction - The company introduced its development history, competitive advantages, and strategic transformation across four business segments, focusing on industrial gases and hydrogen energy expansion [2][4]. - The gas operation business has achieved significant results, with projects like the Inner Mongolia helium extraction and nitrogen production for lithium iron phosphate plants completed [2][3]. Group 2: Industrial Gas Operations - The company plans to drive gas operations through "self-investment + mergers and acquisitions," primarily in Sichuan, gradually expanding nationwide [2][4]. - The company aims to leverage upstream mineral and clean energy resources to enhance downstream industrial advantages and economic benefits [2][4]. Group 3: Hydrogen Energy Development - A clear development plan for the hydrogen energy industry has been established, focusing on deep low-temperature liquid hydrogen technology and extensive application scenarios [4][5]. - The company has developed a 5 tons/day hydrogen liquefaction capacity and is working on a 30 tons/day large-scale liquefaction technology, achieving leading energy consumption levels domestically [5][6]. Group 4: Partnerships and Collaborations - The company has formed a joint venture with Toyota, establishing Sichuan Shudao Toyota Hydrogen Energy Technology Co., Ltd., with a registered capital of CNY 236 million [8]. - Collaborations with various institutions, including Southwest Jiaotong University and Tsinghua University, have been initiated to accelerate technology transfer and innovation [11][12]. Group 5: Hydrogen Energy Products and Projects - The company has developed a series of hydrogen energy equipment products and initiated several influential demonstration projects, including hydrogen refueling stations in Hubei and Sichuan [6][7]. - The company is actively exploring hydrogen energy applications in low-altitude economy and hydrogen-powered locomotives, focusing on new fueling models [9][10]. Group 6: Policy and Market Strategy - The company is aligning its hydrogen energy initiatives with national and regional policies, particularly in the context of the "dual carbon" goals, to support industry development [10][12]. - Efforts are being made to establish a cooperative ecosystem within the hydrogen energy industry, covering all aspects from production to application [12].

Group 1: Industry Outlook - The retail industry is expected to focus on consumer-centric approaches, returning to brand and academic fields, with a long-term growth trend driven by industry innovation [2][3] - The integration of online and offline services will shape the competitive landscape for the next five years, with an increasing demand for health solutions driven by an aging population [3] Group 2: Strategic Planning - The "14th Five-Year" plan is currently in progress, with three major companies focusing on core business areas: CHC for China Resources Sanjiu, prescription drugs for Tianshili, and traditional Chinese medicine for Kunming Pharmaceutical [4] - The strategic framework is "one core and two wings," aiming for leadership in the pharmaceutical industry through collaboration and mutual empowerment among the three companies [4][5] Group 3: Mergers and Acquisitions - Future acquisitions will focus on both "in-depth" and "external" growth strategies, with an emphasis on consumer health, medical health, and silver health sectors [5] - The company will seek potential brand assets in the CHC sector and explore innovative opportunities in prescription drugs [5] Group 4: Innovation and Product Development - The company has established partnerships for innovative projects, particularly in cardiovascular diseases, with a focus on heart failure treatments [6][7] - The company aims to expand its product pipeline in chronic diseases, especially diabetes, and will adopt diverse methods to acquire new products [7] Group 5: Sales and Financial Performance - The sales model is divided into CHC (retail) and prescription drugs (hospital), with sales expense rates influenced by seasonal factors [8] - The company anticipates stable sales expense rates in the long term, with a projected revenue growth exceeding the industry average, aiming for double-digit growth [9][10] Group 6: Product Progress and Market Position - The 999 Yiqi Qingfei Granules, developed in collaboration with academic experts, fills a market gap for respiratory infection recovery medications and has been included in the National Medical Insurance Directory [11] - The prescription drug business is expected to improve, leveraging synergies with Tianshili to enhance management and operational efficiency [12] Group 7: CHC Business Development - The CHC business has surpassed 10 billion RMB during the "14th Five-Year" period, focusing on brand and product expansion [13][14] - The company aims to maintain market leadership in various health sectors by adapting to consumer needs and optimizing brand strategies [14]

Group 1: Company Overview and Strategy - Zhejiang Xinhengcheng Co., Ltd. focuses on expanding its product lines and enhancing operational efficiency through innovation and cost control [2][3] - The company aims to leverage its "Chemical+" and "Biological+" strategies to capture growth opportunities in nutrition, new materials, and flavor industries [5][6] Group 2: Market Performance and Product Development - The market demand for methionine, a key amino acid, is expected to grow steadily due to global population increase and rising health awareness [3] - The company has completed the construction and debugging of a 70,000-ton methionine expansion project, which will be launched based on market conditions [3][4] Group 3: New Projects and Capacity Expansion - The nylon new materials project in Tianjin has commenced pile foundation construction, focusing on an integrated production chain for "adiponitrile-adipamide-nylon 66" [4] - The company plans to expand its production capacity for PPS (polyphenylene sulfide) and other materials, with current utilization rates at 100% [4][5] Group 4: Financial Performance and Shareholder Returns - In 2025, the company distributed a total cash dividend of 2.762 billion yuan, maintaining a dividend payout ratio of 30%-50% of net profits [6] - Cumulative cash dividends since listing have reached 16.1 billion yuan, reflecting the company's commitment to rewarding shareholders [6] Group 5: International Expansion and Market Reach - The company exports to over 100 countries, with international sales accounting for more than 50% of total revenue [5] - Overseas subsidiaries have been established in regions such as Hong Kong, Singapore, Germany, and Brazil to enhance market presence [5]

Group 1: Company Overview and Strategic Positioning - Guanglian Aviation is focused on the commercial aerospace sector, with a significant market position in rocket tank manufacturing through its acquisition target, Tianjin Yuefeng, which has an annual production capacity of 50-70 rocket tanks [3] - The company has established strategic partnerships with leading commercial aerospace firms, including Blue Arrow Aerospace and Tianbing Technology, to enhance its collaborative ecosystem [3][4] Group 2: Acquisition Progress and Integration - The acquisition of Tianjin Yuefeng is in a critical phase, with auditing, evaluation, and due diligence progressing as planned, and both parties have reached a consensus on core cooperation terms [3] - Post-acquisition, the company aims to integrate Tianjin Yuefeng into its strategic development and profit assessment framework to activate its existing capacity and market potential [6] Group 3: Risk Management and Resource Allocation - The company employs a comprehensive risk management system to balance resource allocation across multiple sectors, including commercial aerospace, large aircraft, and robotics, ensuring efficient use of technology and capacity [5] - Measures to address potential uncertainties in the release of commercial rocket orders include establishing long-term strategic partnerships, optimizing national capacity layout, and accelerating core technology iterations [7] Group 4: Future Growth and Profitability - The company anticipates that the commercial aerospace business will contribute to profitability following the acquisition, leveraging resource integration and technological collaboration [6] - A focus on enhancing product value through technological barriers and reducing market validation cycles is expected to strengthen market competitiveness [7]